Contemporary Therapeutic Approaches in the Cardiorenal-Metabolic Continuum: Current Perspectives on Diabetes, Chronic Kidney Disease, and Cardiovascular Dysfunction
DOI:
https://doi.org/10.64784/247Keywords:
Cardiorenal syndrome, Type 2 diabetes mellitus, Chronic kidney disease, Heart failure, Cardiorenal-metabolic syndrome, SGLT2 inhibitors, GLP-1 receptor agonists, Finerenone, Cardiovascular disease, Renal protection, Multidisciplinary care, Internal medicineAbstract
Cardiorenal syndrome associated with type 2 diabetes mellitus has emerged as a major global health challenge due to its increasing prevalence, complex pathophysiology, and significant impact on morbidity and mortality. The interaction between cardiovascular disease, chronic kidney disease, and metabolic dysfunction creates a bidirectional cycle of organ damage mediated by inflammation, oxidative stress, endothelial dysfunction, neurohormonal activation, and fibrosis. This review analyzes current evidence regarding the mechanisms linking diabetes with cardiovascular and renal deterioration, emphasizing the concept of the cardiorenal-metabolic continuum. A comprehensive review of contemporary literature was conducted using international scientific databases and clinical practice guidelines. The findings indicate that recent therapeutic advances, particularly sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and non-steroidal mineralocorticoid receptor antagonists, have significantly improved cardiovascular and renal outcomes while reducing disease progression and hospitalization rates. Despite these advances, substantial challenges remain regarding early diagnosis, treatment accessibility, therapeutic implementation, and healthcare disparities. These challenges are especially relevant in Latin American countries, including Mexico, Colombia, and Ecuador, where the burden of diabetes and chronic kidney disease continues to rise. Current evidence supports the adoption of integrated multidisciplinary approaches focused on early detection, comprehensive risk assessment, and evidence-based therapeutic interventions. The transition from organ-centered management toward a cardiorenal-metabolic model represents a fundamental paradigm shift that may contribute to improved patient survival, preservation of organ function, and enhanced quality of life.
References
[1] J. Rangaswami et al., “Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies,” Circulation, vol. 139, no. 16, pp. e840–e878, Apr. 2019, doi: 10.1161/CIR.0000000000000664.
[2] A. B. M. Fernández et al., “Cardiorenal syndrome and diabetes: An evil pairing,” Frontiers in Cardiovascular Medicine, vol. 10, Art. no. 1180404, 2023, doi: 10.3389/fcvm.2023.1180404.
[3] Kidney Disease: Improving Global Outcomes (KDIGO), “KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease,” Kidney International, vol. 102, no. 5S, pp. S1–S127, 2022.
[4] American Diabetes Association Professional Practice Committee, “Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026,” Diabetes Care, vol. 49, Suppl. 1, pp. S246–S265, 2026.
[5] I. H. de Boer et al., “Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO),” Diabetes Care, vol. 45, no. 12, pp. 3075–3090, 2022, doi: 10.2337/dci22-0027.
[6] Kidney Disease: Improving Global Outcomes (KDIGO), “KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease,” Kidney International, vol. 105, no. 4S, 2024.
[7] V. Perkovic et al., “Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy,” The New England Journal of Medicine, vol. 380, no. 24, pp. 2295–2306, 2019, doi: 10.1056/NEJMoa1811744.
[8] H. J. L. Heerspink et al., “Dapagliflozin in Patients with Chronic Kidney Disease,” The New England Journal of Medicine, vol. 383, no. 15, pp. 1436–1446, 2020, doi: 10.1056/NEJMoa2024816.
[9] The EMPA-KIDNEY Collaborative Group, “Empagliflozin in Patients with Chronic Kidney Disease,” The New England Journal of Medicine, vol. 388, no. 2, pp. 117–127, 2023, doi: 10.1056/NEJMoa2204233.
[10] V. Perkovic et al., “Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes,” The New England Journal of Medicine, vol. 391, pp. 109–121, 2024, doi: 10.1056/NEJMoa2403347.
[11] G. L. Bakris et al., “Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes,” The New England Journal of Medicine, vol. 383, no. 23, pp. 2219–2229, 2020, doi: 10.1056/NEJMoa2025845.
[12] B. Pitt et al., “Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes,” The New England Journal of Medicine, vol. 385, no. 24, pp. 2252–2263, 2021, doi: 10.1056/NEJMoa2110956.
[13] R. Agarwal et al., “Cardiovascular and Kidney Outcomes with Finerenone in Patients with Type 2 Diabetes and Chronic Kidney Disease: The FIDELITY Pooled Analysis,” European Heart Journal, vol. 43, no. 6, pp. 474–484, 2022, doi: 10.1093/eurheartj/ehab777.
[14] J. J. V. McMurray et al., “Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction,” The New England Journal of Medicine, vol. 381, no. 21, pp. 1995–2008, 2019, doi: 10.1056/NEJMoa1911303.
[15] M. Packer et al., “Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure,” The New England Journal of Medicine, vol. 383, no. 15, pp. 1413–1424, 2020, doi: 10.1056/NEJMoa2022190.
[16] S. D. Anker et al., “Empagliflozin in Heart Failure with a Preserved Ejection Fraction,” The New England Journal of Medicine, vol. 385, no. 16, pp. 1451–1461, 2021, doi: 10.1056/NEJMoa2107038.
[17] S. D. Solomon et al., “Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction,” The New England Journal of Medicine, vol. 387, no. 12, pp. 1089–1098, 2022, doi: 10.1056/NEJMoa2206286.
[18] M. Marassi and G. P. Fadini, “The Cardio-Renal-Metabolic Connection: A Review of the Evidence,” Cardiovascular Diabetology, vol. 22, Art. no. 195, 2023, doi: 10.1186/s12933-023-01937-x.
[19] R. Correa-Rotter et al., “Unmet Needs of Chronic Kidney Disease in Latin America: A Review from Expert Virtual Working Group,” Kidney International Reports, vol. 8, no. 5, pp. 954–967, 2023, doi: 10.1016/j.ekir.2023.02.1082.
[20] F. Carrasco-Tenezaca, F. Barrera-Guarderas, K. De la Torre-Cisneros, M. Medina-Escudero, and O. Venegas-Baca, “Time to Develop Chronic Kidney Disease in an Ecuadorian Type 2 Diabetes Mellitus Cohort: Survival Analysis in Primary Care,” Journal of Diabetes and Its Complications, vol. 36, no. 2, Art. no. 108108, 2022, doi: 10.1016/j.jdiacomp.2021.108108.
